Tier 3 — preclinical

A novel fasting mimetic (Mimio) creates fasting-like benefits to hunger control, oxidative stress, and cardiometabolic health in humans

Azure D Grant, Marie Crisel B Erfe, Armenouhi Kazaryan, Paige L Oliver, Jordan Moos, Veronica Luna, Noah Craft, Christopher H Rhodes

Scientific Reports 2026 16(1):7812

Bibliography

PubMed: PMID 41720867
PubMed Central: PMC12953901
DOI: 10.1038/s41598-026-38495-7
Funding: Funded by Mimio Health, LLC.
Competing interests: Christopher H. Rhodes is affiliated with Mimio Health and reviewed generated results; the study was funded by Mimio Health LLC. Other authors reported no competing interests.

Study snapshot

Design	Decentralized double-blind randomized placebo-controlled trial of a multi-ingredient supplement
Model	Overweight older adults with elevated HbA1c
Sample	42 evaluated (23 intervention, 19 placebo)
Intervention	Mimio containing spermidine, nicotinamide, palmitoylethanolamide and oleoylethanolamide versus placebo before the first meal
Duration	8 weeks after 2-week baseline
Endpoints	Hunger and satiety; Digestive symptoms; Total and LDL cholesterol; LDL particle number; Oxidized LDL; Fasting glucose; Cognition; Adverse effects

What the study showed, in plain terms

A 2026 randomized trial found that the Mimio multi-ingredient formulation improved several hunger, lipid, oxidative-stress and glucose measures compared with placebo over eight weeks.

Key findings

This is credible finished-formula evidence for Mimio, not evidence that spermidine alone produced the cardiometabolic effects. Cognition did not differ significantly from placebo, and adverse-event rates were similar.

What this study can and cannot tell us

Small trial, short duration, multiple outcomes and four active ingredients. Several authors were affiliated with People Science, and Christopher H Rhodes was affiliated with Mimio Health LLC, making commercial context important.

Editorial review

Reviewed by the Biohack Blueprint research team

Khaled Mahmoud